Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors

Tomer Meirson, Alessandro Genna, Nikola Lukic, Tetiana Makhnii, Joel Alter, Ved P. Sharma, Yarong Wang, Abraham O. Samson, John S. Condeelis, Hava Gil-Henn

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Metastatic dissemination of cancer cells from the primary tumor and their spread to distant sites in the body is the leading cause of mortality in breast cancer patients. While researchers have identified treatments that shrink or slow metastatic tumors, no treatment that permanently eradicates metastasis exists at present. Here, we show that the ABL kinase inhibitors imatinib, nilotinib, and GNF-5 impede invadopodium precursor formation and cortactin-phosphorylation dependent invadopodium maturation, leading to decreased actin polymerization in invadopodia, reduced extracellular matrix degradation, and impaired matrix proteolysis-dependent invasion. Using a mouse xenograft model we demonstrate that, while primary tumor size is not affected by ABL kinase inhibitors, the in vivo matrix metalloproteinase (MMP) activity, tumor cell invasion, and consequent spontaneous metastasis to lungs are significantly impaired in inhibitor-treated mice. Further proteogenomic analysis of breast cancer patient databases revealed co-expression of the Abl-related gene (Arg) and cortactin across all hormone- and human epidermal growth factor receptor 2 (HER2)-receptor status tumors, which correlates synergistically with distant metastasis and poor patient prognosis. Our findings establish a prognostic value for Arg and cortactin as predictors of metastatic dissemination and suggest that therapeutic inhibition of ABL kinases may be used for blocking breast cancer metastasis.

Original languageEnglish (US)
Pages (from-to)22163-22188
Number of pages26
JournalOncotarget
Volume9
Issue number31
DOIs
StatePublished - Apr 24 2018

Fingerprint

Phosphotransferases
Cortactin
Breast Neoplasms
Neoplasm Metastasis
abl Genes
Neoplasms
Matrix Metalloproteinases
Heterografts
Polymerization
Proteolysis
Extracellular Matrix
Podosomes
Actins
Therapeutics
Phosphorylation
Research Personnel
Databases
Hormones
Lung
Mortality

Keywords

  • ABL kinases
  • Cancer metastasis
  • In vivo
  • Inhibitors
  • Invadopodia

ASJC Scopus subject areas

  • Oncology

Cite this

Meirson, T., Genna, A., Lukic, N., Makhnii, T., Alter, J., Sharma, V. P., ... Gil-Henn, H. (2018). Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Oncotarget, 9(31), 22163-22188. https://doi.org/10.18632/oncotarget.25243

Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. / Meirson, Tomer; Genna, Alessandro; Lukic, Nikola; Makhnii, Tetiana; Alter, Joel; Sharma, Ved P.; Wang, Yarong; Samson, Abraham O.; Condeelis, John S.; Gil-Henn, Hava.

In: Oncotarget, Vol. 9, No. 31, 24.04.2018, p. 22163-22188.

Research output: Contribution to journalArticle

Meirson, T, Genna, A, Lukic, N, Makhnii, T, Alter, J, Sharma, VP, Wang, Y, Samson, AO, Condeelis, JS & Gil-Henn, H 2018, 'Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors', Oncotarget, vol. 9, no. 31, pp. 22163-22188. https://doi.org/10.18632/oncotarget.25243
Meirson, Tomer ; Genna, Alessandro ; Lukic, Nikola ; Makhnii, Tetiana ; Alter, Joel ; Sharma, Ved P. ; Wang, Yarong ; Samson, Abraham O. ; Condeelis, John S. ; Gil-Henn, Hava. / Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. In: Oncotarget. 2018 ; Vol. 9, No. 31. pp. 22163-22188.
@article{25807d2ab61640cda94f967560aae9f3,
title = "Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors",
abstract = "Metastatic dissemination of cancer cells from the primary tumor and their spread to distant sites in the body is the leading cause of mortality in breast cancer patients. While researchers have identified treatments that shrink or slow metastatic tumors, no treatment that permanently eradicates metastasis exists at present. Here, we show that the ABL kinase inhibitors imatinib, nilotinib, and GNF-5 impede invadopodium precursor formation and cortactin-phosphorylation dependent invadopodium maturation, leading to decreased actin polymerization in invadopodia, reduced extracellular matrix degradation, and impaired matrix proteolysis-dependent invasion. Using a mouse xenograft model we demonstrate that, while primary tumor size is not affected by ABL kinase inhibitors, the in vivo matrix metalloproteinase (MMP) activity, tumor cell invasion, and consequent spontaneous metastasis to lungs are significantly impaired in inhibitor-treated mice. Further proteogenomic analysis of breast cancer patient databases revealed co-expression of the Abl-related gene (Arg) and cortactin across all hormone- and human epidermal growth factor receptor 2 (HER2)-receptor status tumors, which correlates synergistically with distant metastasis and poor patient prognosis. Our findings establish a prognostic value for Arg and cortactin as predictors of metastatic dissemination and suggest that therapeutic inhibition of ABL kinases may be used for blocking breast cancer metastasis.",
keywords = "ABL kinases, Cancer metastasis, In vivo, Inhibitors, Invadopodia",
author = "Tomer Meirson and Alessandro Genna and Nikola Lukic and Tetiana Makhnii and Joel Alter and Sharma, {Ved P.} and Yarong Wang and Samson, {Abraham O.} and Condeelis, {John S.} and Hava Gil-Henn",
year = "2018",
month = "4",
day = "24",
doi = "10.18632/oncotarget.25243",
language = "English (US)",
volume = "9",
pages = "22163--22188",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "31",

}

TY - JOUR

T1 - Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors

AU - Meirson, Tomer

AU - Genna, Alessandro

AU - Lukic, Nikola

AU - Makhnii, Tetiana

AU - Alter, Joel

AU - Sharma, Ved P.

AU - Wang, Yarong

AU - Samson, Abraham O.

AU - Condeelis, John S.

AU - Gil-Henn, Hava

PY - 2018/4/24

Y1 - 2018/4/24

N2 - Metastatic dissemination of cancer cells from the primary tumor and their spread to distant sites in the body is the leading cause of mortality in breast cancer patients. While researchers have identified treatments that shrink or slow metastatic tumors, no treatment that permanently eradicates metastasis exists at present. Here, we show that the ABL kinase inhibitors imatinib, nilotinib, and GNF-5 impede invadopodium precursor formation and cortactin-phosphorylation dependent invadopodium maturation, leading to decreased actin polymerization in invadopodia, reduced extracellular matrix degradation, and impaired matrix proteolysis-dependent invasion. Using a mouse xenograft model we demonstrate that, while primary tumor size is not affected by ABL kinase inhibitors, the in vivo matrix metalloproteinase (MMP) activity, tumor cell invasion, and consequent spontaneous metastasis to lungs are significantly impaired in inhibitor-treated mice. Further proteogenomic analysis of breast cancer patient databases revealed co-expression of the Abl-related gene (Arg) and cortactin across all hormone- and human epidermal growth factor receptor 2 (HER2)-receptor status tumors, which correlates synergistically with distant metastasis and poor patient prognosis. Our findings establish a prognostic value for Arg and cortactin as predictors of metastatic dissemination and suggest that therapeutic inhibition of ABL kinases may be used for blocking breast cancer metastasis.

AB - Metastatic dissemination of cancer cells from the primary tumor and their spread to distant sites in the body is the leading cause of mortality in breast cancer patients. While researchers have identified treatments that shrink or slow metastatic tumors, no treatment that permanently eradicates metastasis exists at present. Here, we show that the ABL kinase inhibitors imatinib, nilotinib, and GNF-5 impede invadopodium precursor formation and cortactin-phosphorylation dependent invadopodium maturation, leading to decreased actin polymerization in invadopodia, reduced extracellular matrix degradation, and impaired matrix proteolysis-dependent invasion. Using a mouse xenograft model we demonstrate that, while primary tumor size is not affected by ABL kinase inhibitors, the in vivo matrix metalloproteinase (MMP) activity, tumor cell invasion, and consequent spontaneous metastasis to lungs are significantly impaired in inhibitor-treated mice. Further proteogenomic analysis of breast cancer patient databases revealed co-expression of the Abl-related gene (Arg) and cortactin across all hormone- and human epidermal growth factor receptor 2 (HER2)-receptor status tumors, which correlates synergistically with distant metastasis and poor patient prognosis. Our findings establish a prognostic value for Arg and cortactin as predictors of metastatic dissemination and suggest that therapeutic inhibition of ABL kinases may be used for blocking breast cancer metastasis.

KW - ABL kinases

KW - Cancer metastasis

KW - In vivo

KW - Inhibitors

KW - Invadopodia

UR - http://www.scopus.com/inward/record.url?scp=85045956274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045956274&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.25243

DO - 10.18632/oncotarget.25243

M3 - Article

VL - 9

SP - 22163

EP - 22188

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 31

ER -